July 26, 2026The Journal of Clinical Endocrinology & Metabolism0 citationsOpen Access
View Full PaperTreatment of severe hypertriglyceridemia: a new era dawns
Key Result
Emerging therapies targeting triglyceride metabolism offer promising new strategies for managing severe hypertriglyceridemia, though their current use remains limited to selected patient populations.
Key Points
- The aim is to address the challenges of managing severe hypertriglyceridemia and associated cardiovascular risks.
- Review of novel therapeutic strategies targeting triglyceride metabolism.
- Investigation of genetic variants affecting triglyceride levels and associated cardiovascular risk.
- Summary of ongoing clinical developments for emerging therapies.
- Identified novel therapeutic targets that are in clinical development.
- Emerging treatments show promise in reducing triglyceride levels and managing associated risks.
- Highlighted therapeutic strategies could lead to improved management options for select patient populations.
Structured PICO
Do emerging therapies targeting triglyceride metabolism reduce triglyceride levels and associated risks in patients with severe hypertriglyceridemia?
P
Population
Patients with severe hypertriglyceridemia (triglycerides > 500 mg/dL) or extreme hypertriglyceridemia (> 1000 mg/dL)
I
Intervention
Emerging therapies targeting triglyceride metabolism (e.g., gene or protein inhibitors)
O
Outcome
Reduction of triglyceride levels and mitigation of associated risks (cardiovascular risk and acute pancreatitis)surrogate
This review highlights the emergence of novel therapies targeting triglyceride metabolism to address the unmet medical need of severe hypertriglyceridemia.
Abstract
Abstract Context Hypertriglyceridemia (HTG) is a well-established independent cardiovascular risk factor. Severe (triglycerides TGs 500 mg/dL) or extreme HTG ( 1000 mg/dL) that persist despite the correction of secondary causes are also associated with a markedly increased risk of recurrent acute pancreatitis and represent a substantial unmet medical need. Several novel therapies are progressively emerging and being incorporated into the treatment landscape for the management of severe HTG (sHTG) and associated risks. Evidence acquisition Naturally occurring loss-of-function variants in genes involved in TG metabolism have been identified; carriers of these variants tend to exhibit a favorable lipid profile and reduced cardiovascular risk. Therapeutic strategies have been developed to inhibit these genes or their corresponding proteins through diverse mechanisms of action. In addition, several other proteins and hormones influencing TG metabolism have been identified in the last decade and have emerged as promising targets for sHTG treatment. Evidence synthesis This review summarizes novel therapeutic targets, mechanisms of action, and the ongoing clinical development of emerging treatments aimed at improving the management of TG-rich lipoproteins, reducing TG levels and mitigating associated risks. Conclusion sHTG remains an important unmet medical need. Considerable research efforts are currently focused on the development of innovative, effective, and safe therapeutic interventions aimed at reducing the risks associated with sHTG. At present, the use of most of these emerging therapies remains limited to selected patient populations, while broader indications continue to be investigated.
Cite This Study
Larouche et al. (Thu,) conducted a review in Severe hypertriglyceridemia. Novel therapies targeting triglyceride metabolism was evaluated. Emerging therapies targeting triglyceride metabolism offer promising new strategies for managing severe hypertriglyceridemia, though their current use remains limited to selected patient populations.